Interview with CEO Sara Barrington of Verici DX

Why It Matters

Verici DX’s accelerating adoption could redefine kidney‑transplant monitoring, delivering significant upside as the firm moves toward full‑market coverage and profitability.

Key Takeaways

• Q1 test volumes rose 32% sequentially, beating expectations.
• New sales hires driving trust‑building, champion‑physician adoption across centers.
• Average patient testing cadence estimated at 12 times per year.
• Company targets 100% transplant center coverage, may quadruple sales team.
• Cash runway extends to H2 2026, supporting growth to profitability.

Summary

In a Vox Markets interview, Verici DX CEO Sara Barrington highlighted a robust Q1, with test volumes climbing 32% sequentially and surpassing internal forecasts. The surge stems from a recent fundraising round that funded the recruitment of seasoned sales professionals, whose focus on trust‑building and champion‑physician engagement is beginning to bear fruit. Barrington explained the multi‑step adoption cycle: clinicians receive a few trial orders, evaluate performance, then expand usage to specific sub‑populations such as delayed graft function or BK virus. Using industry protocols, the company estimates a weighted‑average testing cadence of about twelve assays per patient, though most receive around seven in the first year. Currently, Verici DX serves roughly 20% of the 180 addressable transplant centers, aiming to reach full coverage by scaling its sales force fourfold. The CEO also addressed financial runway, confirming that cash reserves extend through the second half of 2026, sufficient to fund the aggressive sales expansion and drive the business toward profitability. Analysts note that the stock trades near half a penny against a target price of £2.90, implying substantial upside if the growth trajectory holds. Overall, Verici DX is positioning its cell‑free DNA test as a standard component of post‑transplant monitoring, leveraging data‑driven protocols and deep clinician relationships to lock in recurring revenue and capture a sizable share of the kidney‑transplant diagnostics market.

Original Description

In this upbeat interview, CEO Sara Barrington of Verici DX – a next generation medical diagnostics firm focusing on the global kidney transplant market - takes me through today’s positive and better than expected Q1’26 trading update.